- Home
- SLND vs INZY Comparison
SLND vs INZY Comparison
Compare SLND & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- INZY
- Stock Information
- Founded
- SLND 1900
- INZY 2015
- Country
- SLND United States
- INZY United States
- Employees
- SLND N/A
- INZY N/A
- Industry
- SLND Military/Government/Technical
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- INZY Health Care
- Exchange
- SLND Nasdaq
- INZY Nasdaq
- Market Cap
- SLND 188.8M
- INZY 188.2M
- IPO Year
- SLND N/A
- INZY 2020
- Fundamental
- Price
- SLND $3.49
- INZY $1.35
- Analyst Decision
- SLND Buy
- INZY Strong Buy
- Analyst Count
- SLND 2
- INZY 8
- Target Price
- SLND $5.50
- INZY $17.75
- AVG Volume (30 Days)
- SLND 43.5K
- INZY 770.8K
- Earning Date
- SLND 03-03-2025
- INZY 03-11-2025
- Dividend Yield
- SLND N/A
- INZY N/A
- EPS Growth
- SLND N/A
- INZY N/A
- EPS
- SLND N/A
- INZY N/A
- Revenue
- SLND $1,029,117,999.00
- INZY N/A
- Revenue This Year
- SLND N/A
- INZY N/A
- Revenue Next Year
- SLND $6.18
- INZY N/A
- P/E Ratio
- SLND N/A
- INZY N/A
- Revenue Growth
- SLND N/A
- INZY N/A
- 52 Week Low
- SLND $1.85
- INZY $1.32
- 52 Week High
- SLND $6.16
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- SLND 52.51
- INZY 20.16
- Support Level
- SLND $3.28
- INZY $1.32
- Resistance Level
- SLND $3.59
- INZY $1.44
- Average True Range (ATR)
- SLND 0.22
- INZY 0.25
- MACD
- SLND 0.00
- INZY -0.12
- Stochastic Oscillator
- SLND 42.25
- INZY 1.61
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.